The requirement in CAMR now for Health Canada approval actually isn't mandated by the general council decision, but I don't think anybody, the generics or the innovative drug industry, object to the requirement being in there that safe drugs actually do get exported under the compulsory licence system.
My problem, Mr. Wallace, with any drug is that the “pharmaceutical product” definition in the general council decision was looking at epidemics and serious problems, not lifestyle drugs. Bill C-393 is offside, in my opinion, because it applies to all drugs, not the ones that we see in schedule 1, which is a limited list. That puts it offside there.
My colleague also wanted to add something, so I'll give him my time.